Sugi Predict

Sugi Predict / Compounds / SCHEMBL253540

SCHEMBL253540

SCHEMBL253540

COCCn1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.57
▸ LPL P06858 4/20 0.34
▸ LIPG Q9Y5X9 4/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ TAS2R8 Q9NYW2 1/20 0.33
▸ BACE1 P56817 1/20 0.33
▸ ALOX5AP P20292 1/20 0.32
▸ KDM5B Q9UGL1 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.32
▸ FEN1 P39748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3410296 0.92 FFAR1 (0.52) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL24959140 0.92 FFAR1 (0.52) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL1855038 0.91 FFAR1 (0.55) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL2679381 0.90 FFAR1 (0.53) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL22172433 0.89 FFAR1 (0.47) FFAR1LPLLIPGTAS2R8BACE1
SCHEMBL25011875 0.89 FFAR1 (0.47) FFAR1LPLLIPGTAS2R8BACE1
SCHEMBL1986801 0.89 FFAR1 (0.52) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL27974178 0.86 FFAR1 (0.44) FFAR1TAS2R8BACE1ALOX5APKDM5B
SCHEMBL3004343 0.85 FFAR1 (0.55) FFAR1LPLLIPGDGAT1IRAK4
SCHEMBL17437195 0.85 LPL (0.46) FFAR1LPLLIPGDGAT1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 — — EP disclosed
EP-4724439-A1 HETEROARYL DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2026-04-15 — — EP disclosed
EP-4713095-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2026-03-25 — — EP disclosed
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 AJAX THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 — — US disclosed
EP-4676927-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS Synnovation Therapeutics, Inc. (US) 2026-01-14 — — EP disclosed
EP-3867248-B1 PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-12-10 — — EP disclosed
US-20250320228-A1 PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2025-10-16 — — US disclosed
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
WO-2009154557-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS ASTRAZENECA AB (SE) 2009-12-23 — — WO disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed
EP-2081937-A2 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-07-29 — — EP disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 — — WO disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 — — WO disclosed
WO-2008088881-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2008-07-24 — — WO disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK FFAR1 1712/4885LPL 4318/4885LIPG 3587/4885
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 FFAR1 2539/4885LPL 3777/4885LIPG 2981/4885
US-20260078131-A1 PYRROLO-PYRIDAZINE INHIBITORS OF JAK2 JAK2, JAK1, JAK3 FFAR1 2402/4885LPL 2707/4885LIPG 3309/4885
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET FFAR1 1595/4885LPL 1103/4885LIPG 558/4885
US-20250320228-A1 PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS PDXK, PPIP5K2, IP6K1 FFAR1 3060/4885LPL 4185/4885LIPG 4471/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 FFAR1 415/4885LPL 701/4885LIPG 511/4885
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 FFAR1 1535/4885LPL 1352/4885LIPG 659/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET FFAR1 1595/4885LPL 1103/4885LIPG 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.